"10.1371_journal.pone.0035600","plos one","2012-05-16T00:00:00Z","Oscar Fernández; Javier Agüera; Guillermo Izquierdo; Javier Millán-Pascual; Lluis Ramió i Torrentà; Pedro Oliva; Javier Argente; Yasmina Berdei; Jose Maria Soler; Olga Carmona; Jose Maria Errea; Jordi Farrés; on behalf of the Group on Adherence to IFNb-1b in Spain","Hospital Universitario Carlos Haya de Málaga, Málaga, Spain; Hospital Universitario Reina Sofía Córdoba, Spain; Hospital Virgen de la Macarena, Sevilla, Spain; Hospital La Mancha Centro, Alcázar de San Juan, Spain; Hospital Josep Trueta, Girona, Spain; HUC de Asturias, Oviedo, Spain; Hospital Puerta del Mar, Càdiz, Spain; Hospital de Salamanca, Salamanca, Spain; Hospital de Sant Joan de Déu de Manresa, Manresa, Spain; Hospital de Figueres, Figueres, Spain; Hospital de Barbastro, Barbastro, Spain; Bayer Hispania, Barcelona, Spain","Conceived and designed the experiments: OF. Performed the experiments: OF J. Agüera GI JM LRIT PO J. Argente YB JMS OC JE. Analyzed the data: JF. Wrote the paper: OF. Group on Adherence to IFNb-1b in Spain: OF (18 patients); Hospital Carlos Haya J. Agüera (12 patients); Hospital Universitario Reina Sofía GI (12 patients); Hospital Virgen de la Macarena JM (12 patients); Hospital La Mancha Centro LR L (12 patients); Hospital Josep Trueta AT (10 patients); Hospital Universitario Central de Asturias J. Argente (7 patients); Hospital Puerta del Mar YB (7 patients); Hospital de Salamanca JMSa (7 patients); Hospital de Manresa OC (6 patients); Hospital de FigueresJME (6 patients); Hospital de Barbastro JM. Sanz (4 patients); Hospital Obispo Blanco AL (3 patients); Hospital Obispo Blanco CR (3 patients); Hospital de Barbastro NT (1 patient); Hospital Clínico de Valladolid.","This study was supported by Química Farmacéutica Bayer S.L.and RPS Research Ibérica. RPS Research Ibérica helped in the statistical analysis. The corresponding author (Oscar Fernández, MD, PhD) has received honoraria as consultant in advisory boards, and as chairmen or lecturer in meetings (Bayer-Schering; Biogen-Idec, Merck-Serono, TevA, Novartis and Sanofi-Aventis).He has also participated in clinical trials and other research projects sponsored by Bayer-Schering; Biogen-Idec, Merck-Serono, TevA, Novartis and Sanofi-Aventis. The author (Olga Carmona, MD, PhD) has received honoraria as consultant in advisory boards, and as a lecturer in meetings (Bayer-Schering; Biogen-Idec, Merck-Serono, TevA, Novartis and Sanofi-Aventis). She has also participated in clinical trials and other research projects sponsored by Bayer-Schering; Biogen-Idec, Merck-Serono, Teva, Novartis and Sanofi-Aventis. The remaining authors have declared that they have no conflict of interest. There are no patents, products in development or marketed products to declare. This does not alter the authors adherence to all the PLoS ONE policies on sharing data and materials.","2012","05","Oscar Fernández","OF",13,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA
